ArticleMolecular neurobiology2026
Circulating microRNAs as Promising Biomarkers in Parkinson's Disease.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our study aims to examine possible Parkinson Disease (PD)-related circulating microRNAs (miRNA) and their potential roles and use cases in screening, diagnosis, and the disease progress in Turkish population. For this purpose, we selected 7 promising candidates namely miR-16-1, miR-24-3p, miR-30a, miR-30e, miR-34a, miR-34b, miR-331 from multiple studies and bioinformatic web tools. For our study, 51 PD patients with no other severe disease except for hypertension and 20 healthy matching controls were included. Serum samples were collected from venous blood and stored properly. RNA extraction, reverse transcription and real-time polymerase chain reaction (qPCR) for each pre-determined miRNA were applied to all samples with a strong normalization method to determine expression levels. Additionally, validated miR-24-3p target genes were intersected against publicly available CSF proteomics (PXD011216), PBMC transcriptomics (GSE22491), and serum metabolomics (MTBLS10958) datasets. miR-24-3p expression was also examined in two independent miRNA datasets (GSE269775; GSE16658). Statistical analyses were done using SPSS and Qiagen GeneGlobe webtools. Between PD and the control group, miR-24-3p serum levels were found increased 1.7 times (p = 0.0001). Among patients, miR-331 serum levels changed significantly with UPDRS scores (p = 0.027). Multi-omics analysis identified 21 differentially abundant miR-24-3p target proteins in PD CSF (81% downregulated), three cross-platform concordant targets, and five metabolically linked pathways. miR-24-3p levels may differ in different biological compartments in PD. In serum, miR-24-3p may provide significant value as a diagnostic biomarker with 80.4% sensitivity and 85% specificity. miR-331 might be a candidate for predicting the severity of the disease.
Indexed as
Identifiers
42446817What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.